Kwality Pharmaceuticals Limited has issued a comprehensive postal ballot notice seeking shareholder approval for the appointment of two Independent Directors through remote e-voting facility. The notice, dated February 21, 2026, outlines the company's proposal to strengthen its board governance structure with experienced professionals.

Proposed Director Appointments

The company seeks approval for two special resolutions concerning Independent Director appointments:

Mr. Preetmohinder Singh Bedi - Appointment Details

Dr. Preetmohinder Singh Bedi was initially appointed as Additional Director (Non-Executive, Independent) with effect from January 01, 2026. His proposed term as Independent Director will run from January 01, 2026 to December 31, 2030. Dr. Bedi brings extensive pharmaceutical expertise with over 28 years of experience in the field.

Professional Background:

• Professor in Department of Pharmaceutical Sciences at Guru Nanak Dev University, Amritsar
• Director, Global Ranking and International Collaboration Cell
• Included in 2025 Stanford–Elsevier list of world's top 2% scientists
• Contributed 150 publications to reputed international and national journals
• Holds patents in medicinal chemistry field

Mr. Bhavesh Mahajan - Appointment Details

Mr. Bhavesh Mahajan was appointed as Additional Director (Non-Executive, Independent) with effect from January 28, 2026. His proposed Independent Director term will span from January 28, 2026 to January 27, 2031. Mr. Mahajan contributes significant financial and audit expertise to the board.

Professional Background:

• Chartered Accountant with over 19 years of professional experience
• Senior Partner at M/s Bhavesh Mahajan & Co., Chartered Accountants
• Category-II CA firm empaneled with Reserve Bank of India since 2005
• Extensive experience in statutory audits, banking audits, and regulatory compliance

E-Voting Process and Timeline

The company has engaged National Securities Depository Limited (NSDL) to provide remote e-voting facility to shareholders. The voting process follows a structured timeline:

Regulatory Compliance and Documentation

The postal ballot notice has been issued in compliance with Section 110 of the Companies Act, 2013, and Regulation 30 of SEBI Listing Regulations. The notice is being distributed electronically to shareholders whose email addresses are registered with the company, Bigshare Services Private Limited (Registrar and Transfer Agent), or depositories as on the cut-off date.

Mr. Rishi Mittal (Membership No. A12613), Proprietor of M/s Rishi Mittal & Associates, Practicing Company Secretaries, has been appointed as Scrutinizer to oversee the remote e-voting process. The scrutinizer will ensure fair and transparent conduct of the voting process and submit the final report to the company's Chairman.

Board Recommendation and Shareholder Benefits

The Board of Directors has recommended both special resolutions for shareholder approval. The appointments are expected to enhance the company's governance framework through the appointees' diverse expertise in pharmaceutical research and financial management. Both directors will be entitled to sitting fees for board and committee meetings, aligned with fees paid to other non-executive independent directors.

The results of the postal ballot, along with the Scrutinizer's Report, will be made available on the company's website at www.kwalitypharma.com , NSDL's website, and will be communicated to BSE Limited where the company's equity shares are listed.

Kwality Pharmaceuticals Limited has delivered exceptional financial performance in Q3 FY26, demonstrating strong operational execution and market expansion capabilities. The pharmaceutical company, with four decades of expertise in complex formulation development and manufacturing, reported significant growth across all key financial metrics.

Strong Q3 FY26 Financial Performance

The company's quarterly results showcase robust growth momentum across revenue and profitability metrics:

The quarter-on-quarter performance also remained strong, with revenue growing 11.2% from INR 111.1 crore in Q2 FY26, while EBITDA increased 18.1% and PAT grew 13.3%.

Nine-Month FY26 Results Maintain Growth Trajectory

The nine-month performance reinforces the company's consistent growth story:

Business Expansion and Regulatory Achievements

Kwality Pharmaceuticals achieved several key milestones during Q3 FY26. The company initiated supplies to highly regulated markets including Mexico and South Africa, while securing new product registrations and commencing commercialization of previously received approvals.

The pharmaceutical manufacturer successfully completed EU-GMP, Russian, and Ukraine audits, enabling entry into new regulated geographies. The company also participated in CPHI Worldwide, Milan, enhancing engagement with global customers and partners.

Manufacturing and Development Capabilities

The company operates six specialized manufacturing units with comprehensive capabilities:

Four of the five operational units have EU-GMP approval, with the company maintaining global certifications across 70+ countries. The organization employs over 1700 people, including 80+ professionals in R&D.

Product Portfolio and Pipeline Progress

Kwality Pharmaceuticals maintains a diversified portfolio with 1000+ developed formulations across 25+ therapeutic areas. The product development pipeline includes 400 commercialized products, 100 ready for filings, and 50 in different stages of development.

During the quarter, the company continued its bioequivalence program for 40+ oral solid dosage products across multiple therapies, completing over three BE studies. The company reported successful EPO pre-clinical outcomes and progressed to the clinical trial stage, while adding three new products to the biologics development pipeline.

Future Growth Strategy and Targets

The company has outlined an ambitious growth strategy targeting INR 650 crore revenue by FY27 with an EBITDA margin of 25%. Key growth drivers include expanding high-margin specialty platforms, unlocking regulated market opportunities through EU-GMP readiness, and achieving operational efficiency through cost optimization.

Ongoing capacity expansion in biologics and oncology, along with the construction of a new hormone manufacturing facility, positions the company for sustained growth in high-value therapeutic segments.